October 24, 2025 07:00 ET | Source: Sagimet Biosciences Inc. Denifanstat met all primary and secondary endpoints versus placebo and…
In a landmark moment for Indian sports, Ruchika Singh has become the first woman cyclist from India to win five…
The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing…
Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…
Conference Call October 20, 8:45am ESTQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment…
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in…
October 13, 2025 21:22 ET | Source: Apollomics Inc. FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc.…
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies…
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants Secondary…